Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2020-10-28 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
关于参与出资设立产业基金暨签订投资协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding its participation in establishing an industrial fund and signing an investment agreement. It details the investment amount, partners, fund structure, management, profit distribution, risks, and approvals by the board and supervisory committee. The document is a formal disclosure of a capital investment and financing activity, not a financial report, earnings release, or management discussion. It does not contain financial statements or quarterly/yearly results. It is not a regulatory filing or report publication announcement since it provides substantive details about the investment transaction. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2020-10-28 Chinese
2020年第三季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2020 Third Quarter Report" of 安徽安科生物工程(集团)股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data such as consolidated and parent company balance sheets, income statements, cash flow statements, and notes on financial performance and shareholder information. The length is substantial (15,000 characters), and it includes actual financial statements and analysis for the third quarter of 2020. This matches the definition of an Interim / Quarterly Report (IR). There is no indication that this is merely an announcement or a certification, and the content is substantive financial data and management discussion for a period shorter than a full fiscal year. 9M 2020
2020-10-28 Chinese
独立董事对相关事项之事前认可意见
Regulatory Filings Classification · 95% confidence The document is a statement of prior approval opinion by independent directors regarding a loan agreement extension and related party transaction. It references regulatory guidelines and company bylaws, and is a formal opinion rather than a financial report or announcement of voting results. It does not contain financial statements or earnings data, nor is it a notice of a meeting or voting results. It is not a certification letter or a short announcement of a report publication. Therefore, it fits best under Regulatory Filings (RNS) as a formal regulatory disclosure that does not fit other specific categories.
2020-10-28 Chinese
关于变更部分募集资金专项账户的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the change of certain special accounts for raised funds (募集资金专项账户) by Anhui Anke Biotechnology Engineering (Group) Co., Ltd. It details the board and supervisory committee meetings approving the change, the background of the fundraising, the amounts involved, and the management of the funds. The document does not contain financial statements or detailed financial performance data but focuses on the management and transfer of fundraising accounts. It is not a full annual or interim report, nor an earnings release or audit report. It is a regulatory announcement about capital management and fundraising account changes, which fits the category of Capital/Financing Update (CAP). The document length is 4338 characters, which is relatively short but contains substantive information about capital account changes rather than just announcing a report publication. Therefore, the best classification is CAP with high confidence.
2020-10-28 Chinese
国元证券股份有限公司关于公司借款协议展期暨关联交易的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from Guoyuan Securities Co., Ltd. regarding the extension of a loan agreement and related party transaction involving Anhui Anke Biotechnology (Group) Co., Ltd. It includes extensive information about the loan extension, the related party transaction, company background, financial data, board and independent directors' opinions, and the sponsor's review. The document is not a brief announcement but a comprehensive review and opinion report on a specific financial transaction and related party matters. It does not fit categories like Annual Report, Earnings Release, or Call Transcript. It is not a simple announcement or certification but a detailed audit and opinion on a related party transaction and loan extension. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests, excluding full annual reports. Therefore, the correct classification is AR with high confidence. 9M 2020
2020-10-28 Chinese
国元证券股份有限公司关于公司部分募集资金投资项目延期的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from Guoyuan Securities regarding the delay in certain fundraising investment projects of Anhui Anke Biotechnology (Group) Co., Ltd. It discusses the use of raised funds, project progress, reasons for delay, and the impact of the delay. It includes financial figures related to fundraising and investment projects, and mentions regulatory compliance and board approvals. The document is not a full annual or interim report, nor is it a simple announcement or certification. It is a specialized report related to capital raising and investment project updates, specifically about the delay in the use of raised funds. This fits best under the category of Capital/Financing Update (CAP), as it provides substantive information on fundraising and capital use changes, not just an announcement or a regulatory filing.
2020-10-28 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.